In a report released today, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Precigen (PGEN – Research Report), with a price target of $6.00. The company’s shares closed yesterday at $1.24.
Ramakanth covers the Healthcare sector, focusing on stocks such as Vericel, ImmunoGen, and Surgalign Holdings. According to TipRanks, Ramakanth has an average return of -19.5% and a 23.02% success rate on recommended stocks.
Precigen has an analyst consensus of Moderate Buy, with a price target consensus of $10.00, a 706.45% upside from current levels. In a report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $14.00 price target.
See the top stocks recommended by analysts >>
Based on Precigen’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.18 million. In comparison, last year the company earned a revenue of $24.22 million and had a GAAP net loss of $25.03 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It focuses on programming biological systems to alleviate disease, remediate environmental challenges, and provide sustainable food and industrial chemicals. The product pipeline includes Isobutanol, Isobutyraldehyde, Farnesene, and Isoprene. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.
Read More on PGEN:
- Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025
- PGEN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Precigen receives FDA Breakthrough Therapy Designation for PRGN-2012
